Evidence-based·Updated November 19, 2026·How we grade evidence

Mazdutide

PeptideInvestigational weight-loss drug (not FDA-approved)

Mazdutide is a once-weekly injection that acts on the GLP-1 and glucagon receptors. It is approved in China for weight management and type 2 diabetes but not in the US. In Chinese phase 3 trials, adults lost an average of 11.0% to 14.0% of body weight over 48 weeks on 4 mg or 6 mg, and 16.65% over 60 weeks on 9 mg, compared with almost no change on placebo. In a US phase 2 trial, higher doses up to 16 mg produced more weight loss but more people stopped because of side effects.

Taking Mazdutide with other supplements or medications?Check your whole list for interactions. Free, no account.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

In the US, adults with obesity or type 2 diabetes who qualify for and choose to join a registered clinical trial; everyone else can ask a doctor about approved options

Common dosing range

No FDA-approved dose. Chinese phase 3 trials studied 4 mg, 6 mg or 9 mg once weekly; a US phase 2 trial studied 3 to 16 mg

When to expect effects

Weight loss measured at 24 to 60 weeks; blood sugar at 24 to 28 weeks

Watch out for

Not FDA-approved and cannot be prescribed in the US outside a trial; FDA has warned sellers of unapproved "research" mazdutide. Vomiting and nausea were very common in the 9 mg trial, and the published phase 3 trials enrolled only Chinese adults

What is it

Mazdutide is an investigational drug in the United States: it is not FDA-approved for any use, so it cannot be prescribed in the US outside a clinical trial, and any product sold in the US as mazdutide (including vials labeled "for research use only") is unapproved and unverified. FDA has warned companies that illegally sold unapproved drugs containing mazdutide falsely labeled "for research purposes" or "not for human consumption" for human use. Outside the US, China approved mazdutide in June 2025 for long-term weight management, together with diet and physical activity, in adults with a BMI of 28 or more, or 24 or more with at least one weight-related condition, and in September 2025 for blood sugar control in adults with type 2 diabetes, according to a published drug review. It was developed by Innovent Biologics together with Eli Lilly, which uses the code LY3305677. A Lilly-funded phase 2 trial in US adults has been published; the published phase 3 trials cited here were all done in China, and the two phase 3 obesity trials were sponsored by Innovent.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You meet the entry criteria of a registered mazdutide trial (listed on ClinicalTrials.gov) and decide with the study team that you want to take part
You live in the US and would rather wait to see whether FDA approves it, while discussing approved weight-loss or diabetes medicines with a prescriber
You live in China, where it is approved, and a doctor there prescribes it and monitors you

Probably skip if…

You would be buying it online or from a "research peptide" seller in the US: FDA has warned companies selling mazdutide this way
You have a personal or family history of medullary thyroid cancer or MEN 2, or you have had pancreatitis; people with these conditions were excluded from GLORY-1
You have moderate to severe depression or a history of a suicide attempt, which were exclusion criteria in GLORY-1, so the drug's effects in these groups are not known
You are pregnant, trying to become pregnant or breastfeeding

Evidence at a glance

weight loss in Chinese adults with obesity or overweight

Good Evidence
Effect
-14.01% on 6 mg vs +0.30% on placebo at 48 weeks (GLORY-1); 15.15 percentage points more than placebo on 9 mg at 60 weeks (GLORY-2)
Best fit
Chinese adults with obesity, or overweight with a weight-related condition
Time
Measured at 32 to 60 weeks; 32 weeks was the primary time point in GLORY-1

blood sugar (HbA1c) in type 2 diabetes

Good Evidence
Effect
HbA1c 1.43 to 2.02 percentage points lower than placebo (DREAMS-1); 0.24 to 0.30 points lower than dulaglutide (DREAMS-2)
Best fit
Chinese adults with type 2 diabetes on diet and exercise or oral diabetes medicines
Time
Measured at 24 to 28 weeks

weight loss in US adults with obesity

Limited Evidence
Effect
6.5 to 17.2 percentage points more weight loss than placebo at 32 weeks
Best fit
US adults with obesity without type 2 diabetes
Time
Measured at 32 weeks, with further loss at 48 weeks

Evidence for 3 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

weight loss in Chinese adults with obesity or overweight

Disease adjunct
Good Evidence

In GLORY-1, a phase 3 trial in China, 610 adults with a BMI of 28 or more, or 24 to under 28 with a weight-related condition, received mazdutide 4 mg or 6 mg weekly or placebo. At 48 weeks, body weight fell by 11.00% (4 mg) and 14.01% (6 mg), compared with a 0.30% gain on placebo, and 35.7% and 49.5% lost at least 15%, compared with 2.0%. In GLORY-2, 461 Chinese adults with a BMI of 30 or more (average age 33.9, 16.1% with type 2 diabetes) lost 16.65% on 9 mg over 60 weeks, compared with 1.50% on placebo. Both trials were funded by Innovent Biologics, the Chinese developer. They enrolled only Chinese adults and did not test heart outcomes.

Effect size
-14.01% on 6 mg vs +0.30% on placebo at 48 weeks (GLORY-1); 15.15 percentage points more than placebo on 9 mg at 60 weeks (GLORY-2)
Time to effect
Measured at 32 to 60 weeks; 32 weeks was the primary time point in GLORY-1
Best fit
Chinese adults with obesity, or overweight with a weight-related condition
Less likely
Other populations, who were not in the phase 3 trials; people who cannot tolerate nausea and vomiting

Bottom line: Clear weight loss in two Chinese phase 3 trials; results in other populations rest on phase 2 data.

blood sugar (HbA1c) in type 2 diabetes

Biomarker support
Good Evidence

In two phase 3 trials in Chinese adults with type 2 diabetes, mazdutide lowered HbA1c. In DREAMS-1, 320 adults on diet and exercise alone (average HbA1c 8.24%) saw HbA1c fall by 1.57 (4 mg) and 2.15 (6 mg) percentage points at 24 weeks, compared with 0.14 on placebo. In DREAMS-2, 731 adults on oral diabetes medicines had larger HbA1c reductions than with dulaglutide 1.5 mg after 28 weeks (0.24 and 0.30 points more) and lost 3.78% to 5.76% more body weight. Both trials were short and did not measure diabetes complications.

Effect size
HbA1c 1.43 to 2.02 percentage points lower than placebo (DREAMS-1); 0.24 to 0.30 points lower than dulaglutide (DREAMS-2)
Time to effect
Measured at 24 to 28 weeks
Best fit
Chinese adults with type 2 diabetes on diet and exercise or oral diabetes medicines
Less likely
People on insulin and non-Chinese populations, who were not in these trials

Bottom line: It lowered blood sugar more than placebo and a little more than dulaglutide in short trials.

weight loss in US adults with obesity

Disease adjunct
Limited Evidence

In a phase 2 trial at 24 US centers, 179 adults with obesity, or overweight with a weight-related condition, and without type 2 diabetes received mazdutide 3 to 6 mg, 10 mg or 16 mg weekly, or placebo, for 48 weeks. At 32 weeks, body weight fell by 7.3%, 15.6% and 18.1%, compared with 0.9% on placebo, with further loss by 48 weeks. Discontinuation because of adverse events was highest on 16 mg (20%). The trial was funded by Eli Lilly, was small and short, and its main result assumed people stayed on treatment.

Effect size
6.5 to 17.2 percentage points more weight loss than placebo at 32 weeks
Time to effect
Measured at 32 weeks, with further loss at 48 weeks
Best fit
US adults with obesity without type 2 diabetes
Less likely
People with type 2 diabetes, who were not in this trial

Bottom line: Higher doses gave more weight loss in US adults in one phase 2 trial, at the cost of more people stopping.

How it works

Mazdutide activates two hormone receptors: GLP-1, the target of semaglutide, and the receptor for glucagon. GLP-1 signals reduce appetite, slow stomach emptying and help insulin release after meals. Glucagon is a hormone that normally raises blood sugar, but its receptor is targeted here for its effects on energy use and on the liver. This is the same pair of targets as survodutide, another drug in development. It is injected under the skin once a week, and in trials the dose was raised in steps, for example from 2 mg to 4 mg to 6 mg over 8 weeks in GLORY-1.

How to take it

1. Typical dose
There is no FDA-approved dose. In the Chinese phase 3 trial GLORY-1, participants received 4 mg or 6 mg injected under the skin once a week, starting at 2 mg and raised every 4 weeks. In GLORY-2, participants received 9 mg once weekly. These are studied doses, not recommendations; a prescriber or study team sets the dose.
2. Higher studied dose
A US phase 2 trial studied 3 to 6 mg, 10 mg and 16 mg once weekly for 48 weeks; 20% of people on 16 mg stopped treatment because of adverse events, mostly stomach-related.
3. Timing
Once a week by injection under the skin in trials
4. With food
Food instructions have not been established in the trial reports
5. Split dosing
Not studied; trials used one weekly injection
6. How long to try
Trials lasted 24 to 60 weeks. No long-term data and no results after stopping have been published

What to track

In a trial, the study visits and blood tests the study team schedules
Nausea, vomiting and diarrhea, and signs of dehydration such as dizziness or very little urine
Severe stomach pain that does not go away, with or without vomiting (a possible sign of pancreatitis in this drug class): get urgent care
Mood changes: people with moderate to severe depression were excluded from GLORY-1, so tell your doctor about low mood
Low blood sugar symptoms if you also take insulin or a sulfonylurea

Bottom line: Approved in China for weight management, unapproved in the US: in the US a registered trial is the only legitimate route.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Vomiting (53.1% vs 1.3% on placebo in GLORY-2, at 9 mg)Nausea (46.9% vs 3.2% on placebo in GLORY-2)Diarrhea (39.4% vs 6.5% on placebo in GLORY-2)Decreased appetite (among the most common events in DREAMS-1)

Serious risks

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: no data on mazdutide in pregnancy are published in the trial reports. As a class warning, the labels of approved GLP-1 weight-loss drugs say they may cause fetal harm; the Wegovy label advises stopping semaglutide at least 2 months before a planned pregnancy. Breastfeeding: no data on mazdutide in breast milk or in breastfed infants are published.

Interactions

Insulin and sulfonylureas (such as glipizide, glyburide or glimepiride)High

Class-based, not a finding for mazdutide: the Wegovy (semaglutide) and Zepbound (tirzepatide) labels say that use with insulin or an insulin secretagogue such as a sulfonylurea may increase the risk of low blood sugar, including severe low blood sugar, and that reducing the dose of the insulin or secretagogue may be necessary. Mazdutide has no FDA label.

Semaglutide, tirzepatide or other GLP-1 medicinesHigh

Class-based, not a finding for mazdutide: mazdutide acts on the GLP-1 receptor. The Wegovy label says use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended, and the Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended. GLORY-1 excluded people who had used weight-loss drugs in the 3 months before screening.

Oral medicines with a narrow safety margin (such as warfarin)Moderate

Class-based, not a finding for mazdutide: the Zepbound label says tirzepatide delays stomach emptying and may affect the absorption of medicines taken by mouth, and says to monitor people taking oral medicines with a narrow therapeutic index (for example warfarin); the Wegovy label says to consider increased clinical or laboratory monitoring with such medicines. A study of mazdutide with warfarin, metformin, atorvastatin and digoxin is listed as completed on ClinicalTrials.gov (NCT05815680), but no results are posted or published.

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

In the US, the only legitimate source today is a registered clinical trial: the study is listed on ClinicalTrials.gov with an NCT number, and the study drug is supplied by the trial
In a trial you sign an informed consent form that names the sponsor, the study doctor and what is being tested
In China, it is an approved prescription medicine (approved in June 2025 for weight management and in September 2025 for type 2 diabetes)

Be skeptical of…

"For research use only" or "not for human consumption" mazdutide sold to the public with dosing instructions: FDA has warned companies selling it this way
"Approved, so it is legal in the US": approval in China does not make it FDA-approved
"FDA-registered" or "has an NDC number, so it is approved": FDA says assignment of an NDC number does not denote FDA approval
"Proven to protect the heart": no heart outcome trial results have been published
Imported or resold pens of unknown origin: FDA warns that illegally marketed GLP-1 drugs sold online may be counterfeit or contain the wrong ingredients or amount

Frequently asked questions

Is mazdutide FDA-approved?⌄

No. As of November 19, 2026, it does not appear among FDA's approved drugs, and FDA calls products containing it unapproved drugs. China approved it in June 2025 for long-term weight management in adults and in September 2025 for type 2 diabetes. Only FDA can decide whether it is approved in the US.

Is it legal to buy mazdutide online in the US?⌄

Mazdutide is an unapproved drug in the US. FDA has warned companies that illegally sold it falsely labeled "for research purposes" or "not for human consumption", and it urges people not to buy these products, which are of unknown quality and may be harmful. In the US, a registered clinical trial is the only legitimate way to receive it now.

How does mazdutide compare with semaglutide?⌄

Mazdutide acts on the GLP-1 receptor like semaglutide, plus the glucagon receptor. In Chinese phase 3 trials, average weight loss was 11.00% to 14.01% at 48 weeks on 4 mg or 6 mg, and 16.65% at 60 weeks on 9 mg. DREAMS-3, a Chinese trial comparing mazdutide 6 mg with semaglutide 1 mg in adults with type 2 diabetes and obesity, is listed as completed on ClinicalTrials.gov, but only its design has been published, so comparisons across trials are uncertain.

Why were the main trials only in China?⌄

The published phase 3 trials were sponsored by Innovent Biologics, which develops the drug in China together with Eli Lilly, and China is where it was approved. Eli Lilly has published a phase 2 trial in 179 US adults. Results in Chinese adults may not apply exactly to other populations, which is one reason more trials are needed.

Can I take mazdutide with my supplements or other medicines?⌄

No interaction studies of mazdutide with supplements have been published. Based on the labels of approved GLP-1 medicines, low blood sugar is a risk with insulin or sulfonylureas, the labels say using it with another GLP-1 medicine is not recommended, and slower stomach emptying may affect medicines taken by mouth. Ask a doctor or pharmacist to check your own list.

References by claim

weight loss in Chinese adults with obesity or overweight

Ji et al., 2025 · PubMed (2025) link

Gao et al., 2026 · PMC (2026) link

weight loss in US adults with obesity

Hsia et al., 2026 · PubMed (2026) link

blood sugar (HbA1c) in type 2 diabetes

Zhu et al., 2026 · PubMed (2026) link

Guo et al., 2026 · PubMed (2026) link

Safety

Wegovy (semaglutide) injection and tablets prescribing information · DailyMed (FDA label) link

ClinicalTrials.gov record NCT05607680 (GLORY-1): eligibility criteria · ClinicalTrials.gov link

Zepbound (tirzepatide) prescribing information · DailyMed (FDA label) link

FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss · FDA link

Interaction: Oral medicines with a narrow safety margin (such as warfarin)

ClinicalTrials.gov record NCT05815680: drug interaction study of IBI362 (mazdutide) with metformin, warfarin, atorvastatin and digoxin · ClinicalTrials.gov link

Track Mazdutide with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 19, 2026·Evidence current as of Nov 19, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.